Garajová Ingrid, Ferracin Manuela, Porcellini Elisa, Palloni Andrea, Abbati Francesca, Biasco Guido, Brandi Giovanni
Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Sant'Orsola-Malpighi Hospital, University of Bologna, 40138 Bologna, Italy.
Interdepartmental Centre of Cancer Research "Giorgio Prodi", University of Bologna, 40138 Bologna, Italy.
Int J Mol Sci. 2017 Jul 17;18(7):1547. doi: 10.3390/ijms18071547.
The onset and selection of resistant clones during cancer treatment with chemotherapy or targeted therapy is a major issue in the clinical management of metastatic colorectal cancer patients. It is possible that a more personalized treatment selection, using reliable response-to-therapy predictive biomarkers, could lead to an improvement in the success rate of the proposed therapies. Although the process of biomarker selection and validation could be a long one, requiring solid statistics, large cohorts and multicentric validations, non-coding RNAs (ncRNAs) and in particular microRNAs, proved to be extremely promising in this field. Here we summarize some of the main studies correlating specific ncRNAs with sensitivity/resistance to chemotherapy, anti-VEGF therapy, anti-EGFR therapy and immunotherapy in colorectal cancer (CRC).
在转移性结直肠癌患者的临床管理中，化疗或靶向治疗期间耐药克隆的出现和选择是一个主要问题。使用可靠的治疗反应预测生物标志物进行更个性化的治疗选择，有可能提高所提议治疗的成功率。尽管生物标志物的选择和验证过程可能很长，需要坚实的统计学、大型队列和多中心验证，但非编码RNA（ncRNAs），尤其是微小RNA，在该领域已被证明极具前景。在此，我们总结了一些将特定ncRNAs与结直肠癌（CRC）对化疗、抗血管内皮生长因子（VEGF）治疗、抗表皮生长因子受体（EGFR）治疗和免疫治疗的敏感性/耐药性相关联的主要研究。
